Royalty Pharma Plc (RPRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $39.85B
Last updated: Nov 17, 2026 at 11:06 AM ET
Royalty Pharma Plc (RPRX) Competitors
The companies most similar to Royalty Pharma Plc are Roivant Sciences (ROIV), BridgeBio Pharma (BBIO) and Revolution Medicines (RVMD). Royalty Pharma Plc trades at 12.9x earnings, against a median of 30.0x for the 7 of these companies with a P/E. By market cap, Royalty Pharma Plc ranks 5th of the 13 companies on this page; Vertex Pharmaceuticals (VRTX) is the largest at $136.56B.
Peer Comparison
RPRX's ROIC of 7.6% is above the peer median of 4.8%, and its revenue growth of 13.3% is below the median of 35.0%. It yields 1.37%, while the median peer pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Royalty Pharma Plc (RPRX) | $39.85B | 12.9x | 11.7x | 25.7% | 7.6% | 13.3% | 1.37% |
| Roivant Sciences Ltd (ROIV) | $28.64B | N/A | 679.3x | 0.0% | N/A | 2136.0% | 0.00% |
| BridgeBio Pharma Inc (BBIO) | $15.25B | N/A | 16.0x | -59.8% | -33.0% | 192.6% | 0.00% |
| Revolution Medicines Inc (RVMD) | $37.27B | N/A | 181.6x | 0.0% | -52.1% | -95.2% | 0.00% |
| BeOne Medicines AG (ONC) | $47.58B | 50.0x | 18.7x | 13.9% | 7.5% | 33.8% | 0.00% |
| Jazz Pharmaceuticals PLC (JAZZ) | $15.50B | 18.4x | 3.3x | 4.4% | 3.5% | 10.4% | 0.00% |
| Regeneron Pharmaceuticals Inc (REGN) | $98.84B | 18.4x | 5.7x | 28.5% | 13.7% | 36.3% | 0.39% |
| Insmed Inc (INSM) | $26.58B | N/A | 17.7x | -39.9% | -44.2% | 268.4% | 0.00% |
| Vertex Pharmaceuticals Inc (VRTX) | $136.56B | 30.0x | 10.5x | 30.7% | 14.2% | 11.8% | 0.00% |
| argenx NV ADR (ARGX) | $60.37B | 33.5x | 6.1x | 31.7% | N/A | 52.1% | 0.00% |
| Genmab AS (GMAB) | $31.67B | 35.8x | 19.2x | 17.0% | 4.8% | 16.1% | 0.00% |
| Ascendis Pharma AS (ASND) | $18.06B | N/A | 13.5x | 72.9% | 12.4% | 73.0% | 0.00% |
| Exelixis Inc (EXEL) | $16.84B | 19.3x | 6.9x | 35.4% | N/A | 10.2% | 0.00% |
| Peer median | $30.16B | 30.0x | 14.7x | 15.4% | 4.8% | 35.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Royalty Pharma Plc, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Roivant Sciences Ltd (ROIV) | Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive... | ROIV competitors |
| BridgeBio Pharma Inc (BBIO) | BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. | BBIO competitors |
| Revolution Medicines Inc (RVMD) | Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted... | RVMD competitors |
| BeOne Medicines AG (ONC) | BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe... | ONC competitors |
| Jazz Pharmaceuticals PLC (JAZZ) | Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United... | JAZZ competitors |
| Regeneron Pharmaceuticals Inc (REGN) | Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. | REGN competitors |
| Insmed Inc (INSM) | Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. | INSM competitors |
| Vertex Pharmaceuticals Inc (VRTX) | Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. | VRTX competitors |
| argenx NV ADR (ARGX) | argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases... | ARGX competitors |
| Genmab AS (GMAB) | Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark. | GMAB competitors |
| Ascendis Pharma AS (ASND) | Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark. | ASND competitors |
| Exelixis Inc (EXEL) | Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development... | EXEL competitors |
Frequently Asked Questions About RPRX
Who are Royalty Pharma Plc's main competitors?
The companies most similar to Royalty Pharma Plc include Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Revolution Medicines (RVMD), BeOne Medicines AG (ONC) and Jazz Pharmaceuticals (JAZZ), listed from the closest match.
Who is Royalty Pharma Plc's biggest competitor?
Vertex Pharmaceuticals (VRTX) is the largest of the similar companies at $136.56B; Roivant Sciences (ROIV) is the closest match by business profile, size, sector and industry.
How does RPRX stock compare with its competitors?
RPRX's P/E is 12.9x against a peer median of 30.0x; its P/S is 11.7x against a peer median of 14.7x; its net margin is 25.7% against a peer median of 15.4%.
Which of Royalty Pharma Plc's competitors pays a higher dividend?
Royalty Pharma Plc has a forward dividend yield of 1.37%. None of the similar companies with available yields has a higher forward dividend yield.
Is Royalty Pharma Plc bigger than its competitors?
No. Royalty Pharma Plc is 5th by market cap among the 13 companies on this page; the largest is Vertex Pharmaceuticals (VRTX) at $136.56B.
RPRX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors